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Genetic alterations that lead to uncontrolled 
protein tyrosine kinase (PTK) activity are a hall-
mark of human malignant myeloproliferative 
disorders. Fusion genes involving ABL or 
PDGFR are the molecular correlate of chronic 
myeloproliferative disorders, whereas activating 
mutations of FLT3 are recurrently found in hu-
man acute myeloid leukemia (AML; Chalandon 
and Schwaller, 2005). The success of small mol-
ecules that block oncogenic tyrosine kinase 
activity, such as imatinib-mesylate (Gleevec; 
Novartis), provided a proof of principle for 
targeted antileukemic therapy (Giles et al., 2005). 
However, the successful clinical use of such 
compounds has been challenged by the devel-
opment of drug resistance and a limited clinical 
efficacy in patients with acute leukemia (von 
Bubnoff et al., 2003). To overcome these limi-
tations, identification of critical signaling media-
tors downstream of an oncogenic tyrosine kinase 
is essential to identify new targets that would al-
low the development of an efficient combined 
therapeutic approach. There is strong evidence 
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FLT3-ITD–mediated leukemogenesis is associated with increased expression of oncogenic 
PIM serine/threonine kinases. To dissect their role in FLT3-ITD–mediated transformation, we 
performed bone marrow reconstitution assays. Unexpectedly, FLT3-ITD cells deficient for 
PIM1 failed to reconstitute lethally irradiated recipients, whereas lack of PIM2 induction did 
not interfere with FLT3-ITD–induced disease. PIM1-deficient bone marrow showed defects 
in homing and migration and displayed decreased surface CXCR4 expression and impaired 
CXCL12–CXCR4 signaling. Through small interfering RNA–mediated knockdown, chemical 
inhibition, expression of a dominant-negative mutant, and/or reexpression in knockout cells, 
we found PIM1 activity to be essential for proper CXCR4 surface expression and migration 
of cells toward a CXCL12 gradient. Purified PIM1 led to the phosphorylation of serine 339 in 
the CXCR4 intracellular domain in vitro, a site known to be essential for normal receptor 
recycling. In primary leukemic blasts, high levels of surface CXCR4 were associated with 
increased PIM1 expression, and this could be significantly reduced by a small molecule PIM 
inhibitor in some patients. Our data suggest that PIM1 activity is important for homing and 
migration of hematopoietic cells through modification of CXCR4. Because CXCR4 also 
regulates homing and maintenance of cancer stem cells, PIM1 inhibitors may exert their 
antitumor effects in part by interfering with interactions with the microenvironment.
© 2009 Grundler et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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tion is not limited to leukemia but is also essential for the 
spreading of tumor-initiating cells of many solid tumors (Croker 
and Allan, 2008).
Using bone marrow cells from PIM knockout mice, we 
show that in vivo malignant transformation by the FLT3-ITD 
mutant is independent of PIM2. However, our experiments 
unexpectedly unravel that PIM1 is important for bone marrow 
reconstitution in lethally irradiated hosts. Further functional 
analysis suggests that PIM1 regulates surface CXCR4 expres-
sion in hematopoietic cells lines and in AML blasts. Collec-
tively, our work reveals a previously unknown function of the 
oncogenic PIM1 serine/threonine kinase as regulator of hom-
ing and migration of bone marrow cells involving functional 
interaction with the CXCL12–CXCR4 signaling axis.
RESULTS
To investigate the role of PIM kinases in hematological dis-
eases induced by oncogenic PTKs, we expressed the consti-
tutively active FLT3-ITD mutant in primary mouse bone 
marrow cells. Expression of FLT3-ITD in WT cell induced 
growth factor-independent growth in liquid culture as well as 
in methylcellulose. Compared with WT bone marrow, ex-
pression of FLT3-ITD in PIM1/ cells resulted in a signifi-
cantly lower number of colonies growing with and without 
IL-3 (Fig. 1 A). No differences in colony formation or growth 
properties were observed when FLT3-ITD was expressed 
in bone marrow cells from mice lacking the PIM2 gene 
(PIM2/) compared with WT mice when grown in pres-
ence or in absence of IL-3 (Fig. 1 A). Liquid culture of the 
cells over 5 d revealed no difference in viability but a general 
reduced growth rate of bone marrow cells originating from 
PIM1/ animals compared with PIM2/ or WT mice 
(Fig. S1, B–D). These in vitro results suggest that PIM1, and 
not PIM2, is involved in signaling events that are essential for 
IL-3 and/or FLT3-ITD–regulated proliferation. To further 
study the role of PIMs in FLT3-ITD–mediated leukemogen-
esis in vivo, we performed bone marrow transduction/trans-
plantation experiments using WT or PIM1/ or PIM2/ 
donor mice. Mice that were transplanted with cells lacking 
PIM1 showed no hematological disorder during 1-yr post-
transplant observation (Fig. 1 B). Histological analysis of the 
normal sized spleens of animals that had been transplanted 
with PIM1/ FLT3-ITD–expressing cells did not show any 
significant pathological changes 6 mo after transplant (Fig. S2, 
top). In contrast, all animals that received a transplant of 
FLT3-ITD–transduced bone marrow cells from WT or 
PIM2/ mice developed a myeloproliferative disorder char-
acterized by a massive expansion of EGFP-positive myeloid 
(CD11b+) cells in the peripheral blood assessed by flow cy-
tometry 26 d after transplantation (Fig. 1 C). There was no 
significant difference in survival between recipients of WT 
versus PIM2/ bone marrow transduced with FLT3-ITD, 
with both mice groups succumbing to a fatal disease within a 
median survival time of 108 and 138 d, respectively (Fig. 1 B). 
Histopathological examination of the spleens of sick mice re-
vealed extensive infiltration with neoplastic myeloid cells in 
that most oncogenic tyrosine kinases mediate malignant trans-
formation through parallel activation of several signaling path-
ways such as JAK–STAT, PI3K–AKT, RAS–RAF–MAPK, 
or NF-B (Chalandon and Schwaller, 2005).
Retroviral gene tagging in c-myc–induced lymphomas in 
mice has led to the identification of the PIM family of serine/
threonine kinases that encompasses three members: PIM1, 
PIM2, and PIM3 (Mikkers et al., 2002). Transgenic mouse 
models have demonstrated that PIM kinases exert their onco-
genic potential mainly in cooperation with various onco-
genes. Targeted inactivation of one, two, or all three PIM 
genes resulted in mice with some growth retardation and 
mild defects in steady-state hematopoiesis, but these mice 
were fertile with a normal lifespan (Mikkers et al., 2004). 
PIM1 has been characterized as one of the first target genes of 
STAT5 (Mui et al., 1996). In vitro and in vivo experimental 
work has demonstrated that constitutive STAT5 activation is 
a hallmark of a wide spectrum of hematological malignancies 
and that STAT5 is an essential mediator for transformation by 
oncogenic tyrosine kinases (Schwaller et al., 2000). Interest-
ingly, both PIM1 and PIM2 are frequently overexpressed in 
leukemia and lymphoma as well as in some solid tumors 
(Amson et al., 1989; Mizuki et al., 2003; Hammerman et al., 
2005). As PIM kinases are constitutively active and their ex-
pression is regulated predominantly by transcription and/or 
proteasomal degradation, this suggests that PIM kinases play 
an important role in hematological malignancies. Further in 
vitro functional studies have provided evidence that activa-
tion of PIM1 and/or PIM2 is important for malignant trans-
formation by oncogenic tyrosine kinases such as FLT3-ITD, 
expressed in 25% of human AML cases (Kim et al., 2005; 
Adam et al., 2006; Agrawal et al. 2008). These studies in-
dicated that small molecules inhibiting PIM kinases could 
provide a promising therapeutic avenue for hematological 
malignancies. However, it remains unclear whether one or 
both of the hematopoietically expressed PIMs (PIM1 and 
PIM2) are essential for mediating disease manifestations in-
duced by oncogenic PTKs.
CXCL12, which is also known as SDF1 (stromal cell– 
derived factor 1), mediates signals through the chemokine 
receptor 4 (CXCR4) that are essential for homing and main-
tenance of hematopoietic stem cells (HSCs) in the bone mar-
row niche (Lapidot et al., 2005; Ratajczak et al., 2006). There 
is increasing evidence that CXCR4 is a key regulator of 
homing and retention of leukemic stem cells within the mar-
row niche that allows these cells to escape spontaneous and 
chemotherapy-induced cell death as well as promoting me-
tastasis (Juarez and Bendall, 2004; Burger and Kipps, 2006). 
These findings are supported by the negative prognostic im-
pact of high CXCR4 expression levels in patients with AML 
(Rombouts et al., 2004; Spoo et al., 2007). Consequently, 
targeting leukemic stem cells within the bone marrow by 
disruption of the CXCL12–CXCR4 interaction by small 
molecule inhibitors has been recently proposed (Zeng et al., 
2006; Juarez et al., 2007). There is strong evidence that the 
CXCL12–CXCR4-mediated growth promotion and migra-
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mediated disease might be explained by the inability of PIM1/ 
to reconstitute irradiated animals. During the first series of 
experiments, we applied a nonmyeloablative irradiation dose 
to FVB/N mice (750 rad). To further exclude the possibility 
of a homing failure in PIM1/ cells, we increased the irradi-
ation to a lethal dose of 900 rad and repeated the experi-
ments. Again, animals receiving FLT3-ITD–expressing cells 
from WT and PIM2/ donors developed an identical my-
elolymphoproliferative disorder to that described in the pre-
vious paragraph (unpublished data). In contrast, all recipients 
receiving PIM1/ bone marrow expressing the control vector 
(Mig-IRES-EGFP) alone or FLT3-ITD died rapidly (within 
22 d) because of the lack of bone marrow reconstitution (Fig. 
2 A). Careful examination of the hematologic parameters 
mice that received a transplant of FLT3-ITD–infected WT as 
well as PIM2/ bone marrow cells (Fig. S2, middle and bot-
tom). All mice receiving a transplant of FLT3-ITD–transduced 
bone marrow developed exactly the same mixed myeloid/T 
lymphoid phenotype, irrespective of the genetic background 
of the transplanted bone marrow (Fig. S3). Observation of 
the EGFP+ reconstituted cells revealed significant expansion 
of FLT3-ITD–expressing WT or PIM2/ cells within the 
first month after transplant. In contrast, although detectable 
over several weeks, FLT3-ITD–expressing PIM1/ under-
went no significant expansion (Fig. 1 D).
As bone marrow harvest, as well as the retroviral infection 
rate of WT, PIM1/, or PIM2/ bone marrow cells, did 
not differ (unpublished data), the absence of any FLT3-ITD–
Figure 1. In vitro and in vivo FLT3-ITD–mediated transformation in the presence and absence of PIM serine/threonine kinases. (A) Compara-
tive analysis of clonogenic growth of FLT3-ITD–expressing bone marrow cells from FVB/N (WT) and PIM1/ or PIM2/ mice. 104 cells were sorted 
(EGFP+) 48 h after infection and plated in methylcellulose in presence or absence of IL-3. The figure represents one out of three independent experiments 
performed in triplicates. (B) Kaplan Meier survival plot. WT, PIM1/, or PIM2/ bone marrow was transduced with FLT3-ITD or empty vector (MigRI) as 
indicated and transplanted into sublethally irradiated (750 rad) recipient mice. All mice that underwent transplantation with FLT3-ITD–transduced WT or 
PIM2/ bone marrow died or were sacrificed because of disease conditions. One mouse transplanted with FLT3-ITD–transduced WT bone marrow 
showed extended survival and no signs of disease. n, number of mice transplanted and analyzed. Three independent transplantations were performed (see 
Fig. S3 E for details). (C) Flow cytometric analysis of peripheral blood samples in the course of the disease (26, 52, and 90 d after transplantation). Two-
parameter dot plots show expression of myeloid lineage-specific antigen CD11b versus EGFP. The figure represents one out of three (WT) and four 
(PIM2/) analyzed mice, respectively. (D) Percentage of EGFP-positive leukocytes in the peripheral blood of transplanted mice determined at the indi-
cated time points. Data represents the mean ± SD of three to four analyzed animals as indicated.
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showed that in contrast to animals transplanted with PIM2/ 
and WT cells, in recipients receiving PIM1/ cells the white 
cell, red cell, and platelet counts declined rapidly in the first 
2 wk after transfer (Fig. S4). This unexpected observation 
suggests that PIM1 might play an essential role in early bone 
marrow reconstitution. Although previous work has demon-
strated that PIM1/ bone marrow cells show some growth 
defects (Domen et al., 1993), as shown in colony-forming assays 
(Fig. 1 A), the number of HSCs, as assessed by the determina-
tion of the number of lineage-negative (Lin Sca1+ Kit+) 
cells, was not reduced in PIM1/ when compared with WT 
animals (FVB/N; not depicted). 
The rapid declines in hematopoietic cells of all lineages, 
leading to death of animals within the first month after trans-
plant, suggest that PIM1/ HSCs have not only a proliferation 
defect but also impaired migration and/or homing capacities. 
To understand the role of PIM1 in HSC homing, we per-
formed a series of experiments in which we labeled bone 
marrow cells from WT or PIM1/ mice with a vital dye 
(CFSE), transplanted equal numbers of positively labeled and 
viable cells into lethally irradiated recipients, and determined 
the amount of cells in spleen and bone marrow 4 and 20 h 
after transplant. As shown in Fig. 2 B, a significant time- 
independent decrease in CSFE-labeled cells was observed in 
the bone marrow and spleen after transferring PIM1/ cells 
compared with cells from WT donor animals. No significant 
difference in viability of CFSE-labeled cells was observed be-
tween the genotypes (Fig. 2 C). This finding suggests that 
PIM1/ bone marrow cells are impaired in their capacity to 
home to hematopoietic organs.
The CXCL12–CXCR4 signaling axis has been proposed 
to be essential for homing and migration of hematopoietic 
cells (Juarez and Bendall, 2004; Lapidot et al., 2005; Burger 
and Kipps, 2006; Ratajczak et al., 2006). To explore the role 
of these signaling mediators, we compared WT, PIM1/, and 
PIM2/ cells for their capacity to migrate over a CXCL12 
gradient. As shown in Fig. 3 A, bone marrow cells lacking 
PIM1 are significantly impaired in migration. In contrast, 
PIM2/ bone marrow cells were not defective in migration 
toward CXCL12. Interestingly, we found that bone marrow 
cells from PIM1/ mice, but not PIM2/ mice, expressed 
lower levels of surface CXCR4 when analyzed by flow cy-
tometry (Fig. 3 B) but did not show any differences in the 
expression of other surface molecules involved in homing such 
as the integrins 4 and 5 (Fig. S5). In addition, CXCL12-
induced Ca2+ flux was significantly reduced in bone marrow 
cells lacking PIM1 when compared with WT cells (Fig. 3 C). 
Furthermore, we observed a modest but reproducible im-
pairment of CXCL12-induced phosphorylation of ERK in 
the lineage-negative subpopulation of PIM1/ bone marrow 
cells analyzed by flow cytometry and immunoblotting (Fig. S6 
and not depicted). These observations suggested that the serine/
threonine kinase PIM1 could functionally regulate CXCR4.
To further experimentally address this possibility, PIM1 
expression was knocked down by retrovirally expressed small 
interfering RNAs (siRNAs) in Ba/F3 cells and resulted in a 
Figure 2. PIM1/ bone marrow cells do not reconstitute lethally 
irradiated recipient animals and have an impaired homing capacity. 
(A) Overall survival (Kaplan-Meier plot) of lethally irradiated (900 rad) 
recipients receiving WT, PIM1/, or PIM2/ bone marrow cells. n, num-
ber of mice transplanted and analyzed. Two sets of independent trans-
plantations were performed. (B) Homing of CFSE-labeled bone marrow 
cells from PIM1/ and WT FVB/N mice to the bone marrow (top) and the 
spleen (bottom) of WT recipients. Data represent the mean ± SD of three 
experiments performed in triplicates. (C) Viability of bone marrow cells 
from PIM1/ and WT FVB/N mice 4 and 20 h after CFSE stain. Data rep-
resent the mean ± SD of three experiments performed in duplicates.
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gested that PIM1 regulates CXCR4 surface expression and func-
tion in hematopoietic cells. To further test the hypothesis that 
PIM1 kinase activity is involved in regulation of CXCR4 surface 
expression, we used a recently identified potent small molecule 
inhibitor of human PIM1 (K00486; Pogacic et al., 2007). 
Human JURKAT acute lymphoblastic leukemia cells that ex-
press high levels of PIM1 and surface CXCR4 were used in this 
experiment. Interestingly, as shown in Fig. 4 E, short-term non-
toxic treatment (2 h, 10 µM) with the PIM inhibitor K00486 led 
to a transient but significant decrease of CXCR4 surface expres-
sion and reduced migration of the cells toward a CXCL12 gradi-
ent without affecting cellular viability (Fig. 4 F). Treatment of 
the cells with the PIM inhibitor also impaired CXCL12-induced, 
but not PMA-induced, ERK phosphorylation (Fig. S7 B). These 
results strongly suggested that PIM1 might act as functional regu-
lator of the CXCL12–CXCR4 signaling axis.
significant decrease of CXCR4 surface expression (Fig. 4 A). 
Interestingly, Western blot analysis revealed no change in total 
CXCR4 protein expression (Fig. 4 B). Furthermore, expres-
sion of a dominant-negative PIM1-KD mutant also down-
regulated cell surface CXCR4 expression, suggesting that PIM1 
kinase activity is necessary (Fig. S7 A). These data suggested that 
PIM1 does not influence the total protein level of CXCR4, but 
may control the surface presentation, and that PIM1 activity 
might be necessary. We therefore tested whether the reexpres-
sion of PIM1 in PIM1/ bone marrow cells could rescue 
surface CXCR4 expression and migration toward a CXCL12 
gradient. As shown in Fig. 4 C, retroviral expression of PIM1 in 
bone marrow cells from PIM1/ background increased surface 
CXCR4 expression to the level of WT littermates. In addition, 
expression of PIM1 restored the capability of cells to efficiently 
migrate toward CXCL12 (Fig. 4 D). These results strongly sug-
Figure 3. Decreased steady-state CXCR4 surface expression of PIM1/ bone marrow cells is associated with impaired migration and 
CXCL12-induced signaling. (A) Bone marrow cells from PIM1/, PIM2/, and WT FVB/N mice were allowed to migrate toward a 300-ng/ml CXCL12 
gradient along with background migration as indicated. The migration index was calculated as a percentage of input cells. Data represent the mean ± SD 
of three experiments performed in triplicates. (B) Cell surface expression of CXCR4 of bone marrow cells from PIM1/, PIM2/, and WT mice was ana-
lyzed by staining with PE-conjugated anti–mouse CD184 antibody (open histogram). The level of nonspecific binding was assessed using a PE-conjugated 
rat IgG2b as isotype control (gray histogram). Data represent one out of three experiments. (C) Calcium flux was monitored in freshly isolated WT and 
PIM/ bone marrow cells after stimulation with 300 ng/ml CXCL12. Data represent one out of three experiments.
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Figure 4. PIM1 activity regulates CXCR4 surface expression in hematopoietic cells. (A) Down-regulation of PIM1, but not PIM2, resulted in re-
duced surface expression of CXCR4 in Ba/F3 cells. Ba/F3 cells were retrovirally transduced with pLMP (), pLMP-PIM1, or pLMP-PIM2 (expressing siRNA). 
Cell surface expression of CXCR4 was analyzed by staining with PE-conjugated anti–mouse CD184 antibody (open histogram). The level of nonspecific 
binding was assessed as described in 3B (gray histogram). Data represent one out of three experiments. (B) Down-regulation of PIM1 and PIM2 protein 
expression was confirmed by Western blot analysis. No change in total CXCR4 expression was observed. The figure represents one out of three indepen-
dent experiments. (C) WT and PIM1/ bone marrow was transduced with pMSCV mPIM1-YFP or empty vector (MYFP) as indicated. Cell surface expres-
sion of CXCR4 was analyzed by staining with PE-conjugated anti–mouse CD184 antibody. Data represent the mean of two independent experiments.  
(D) Bone marrow cells from WT and PIM1/ FVB/N mice, transduced with pMSCV mPIM1-YFP or empty vector (MYFP) as indicated, were allowed to mi-
grate toward a 300-ng/ml CXCL12 gradient along with background migration as indicated. The migration index was calculated as a percentage of input 
cells. Data represent the mean ± SD of three independent experiments performed in triplicates (one-way ANOVA: *, P ≤ 0.05). (E) Treatment of human 
JURKAT leukemia cells with a small-molecule PIM1 inhibitor (K00486, 10 µM) leads to a transient but significant reduction of surface CXCR4 expression 
after 2 h (dotted line) and 24 h (gray line). Viability of the cells was not significantly changed within the time of the experiment determined by 7-AAD 
staining (not depicted). Data represent one of three experiments. (F) JURKAT cells were allowed to migrate toward a 100-ng/ml CXCL12 gradient with or 
without pretreatment with 10 µM of the K00486 PIM inhibitor for 2 h. Data represent the mean ± SD of three experiments.
Elevated surface CXCR4 expression has been demon-
strated to be an adverse prognostic marker in patients with 
AML (Rombouts et al., 2004; Spoo et al., 2007). Because 
our results suggest that PIM1 is a regulator of surface CXCR4 
expression, we compared pim1 expression levels in leukemic 
samples that have been previously analyzed for surface CXCR4 
expression (Spoo et al., 2007). A tendency for higher pim1 
expression in AML samples with high CXCR4 surface ex-
pression was observed (P < 0.05; Fig. 5 A, left). In contrast, 
we found no correlation between surface CXCR4 and cxcr4 
messenger RNA (mRNA) levels (Fig. 5 A, right). These re-
sults suggest that PIM1 signaling is necessary for increased 
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gradient of 10 nM CXCL12 was significantly enhanced for 
PIM1-overexpressing cells and was significantly impaired in 
the presence of the PIM inhibitor.
CXCR4 expression is regulated by ligand-induced inter-
nalization and surface reexpression of a significant fraction 
(Busillo and Benovic, 2007). To address a functional connec-
tion of CXCR4 and PIM1, we followed CXCR4 surface ex-
pression in JURKAT cells upon stimulation with CXCL12 in 
presence or absence of the PIM inhibitor (Fig. 6 A). In analogy 
to previous studies, 1.5 h after exposure of JURKAT cells to 
10 nM CXCL12, the majority of surface CXCR4 has been 
internalized (Ding et al., 2003). Washing out of the CXCL12 
after 30 min resulted in rapid reexposure of surface CXCR4 to 
CXCR4 surface expression. When freshly isolated leukemic 
blasts from six patients with newly diagnosed AML express-
ing high surface CXCR4 levels received short-term treat-
ment with the PIM inhibitor (K00486), a significant decrease 
in steady-state surface CXCR4 expression was observed in 
four out of six samples without significantly impaired viabil-
ity (Fig. 5 B). These observations suggest that PIM1 is an im-
portant regulator of surface CXCR4 expression in primary 
human cancer cells. To determine if elevated PIM1 levels 
that are often found in human cancers might affect CXCR4 
function, we evaluated migration of Ba/F3 cells stably over-
expressing human PIM1 toward a CXCL12 gradient (Pogacic 
et al., 2007). As shown in Fig. 5 C, transmigration toward a 
Figure 5. Expression and regulation of PIM1 and CXCR4 in primary AML blasts. (A) Expression of PIM1 and CXCR4 mRNA in leukemic cells from 
AML patients with high versus low surface CXCR4 expression (as described in Spoo et al. [2007]) by quantitative real-time PCR analysis. The values are 
normalized to GAPDH levels and represent each AML patient (diamond) and median values (bars) of two independent experiments performed in triplicate 
(one-way ANOVA: *, P ≤ 0.05). (B) Regulation of surface CXCR4 expression in primary blasts from four out of six AML patients upon treatment with the 
K00486 PIM inhibitor. Data represents one of two independent experiments. (C) BaF/3 cells stably overexpressing human PIM1, as well as WT BaF/3 cells, 
were allowed to migrate toward a 10-nM CXCL12 gradient in the presence or absence of 10 µM of the K00486 PIM inhibitor for 2 h. The migration index 
was calculated as a percentage of input cells. Data represent the mean ± SD of three experiments (one-way ANOVA: **, P ≤ 0.01).
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The cells were stimulated with 10 nM CXCL12 for 30 min 
before washing out the ligand. Similar to treatment with PIM 
inhibitor, siRNA-mediated PIM1 knockdown in JURKAT 
cells significantly impaired CXCR4 surface reexpression (mea-
sured 1, 2, and 3 h after washout) to 50% of the WT control 
cells (Fig. 6 C). Collectively, these experiments suggest that 
PIM1 might play an important role for proper surface reex-
pression of CXCR4.
Functional regulation of CXCR4 by PIM1 activity raised 
the question of whether PIM1 kinase directly modifies the 
CXCR4 receptor. In support of a direct association, immu-
nolocalization studies in JURKAT cells showed partially 
overlapping signals for CXCR4 and PIM1 predominantly in 
the cytoplasm (Fig. S8 B). CXCR4 undergoes ligand-depen-
dent and ligand-independent endocytosis and surface re-
expression depending on the integrity of the intracellular 
C-terminal domain rich in serine and threonine residues 
80% of the starting level. Pretreatment of the cells with 10 µM 
of the PIM inhibitor for 1 h before CXCL12 addition in-
creased the fraction of internalized CXCR4 to >90% after 1.5 h. 
Interestingly, surface CXCR4 reappearance after washing out 
was significantly impaired, reading only 40% of the starting 
level. To visualize the observed effects, we analyzed CXCR4 
expression by immunofluorescent staining at the end of the 
experiment (3.5 h). As shown in Fig. 6 B, CXCL12 treatment 
resulted in internalization of a significant fraction of CXCR4 
and washing out almost completely restored surface CXCR4. 
In presence of the PIM inhibitor, CXCL12 treatment also led 
to CXCR4 internalization; however, after washing out, an 
important fraction of the receptor remained internalized.
We next followed surface CXCR4 expression in JUR-
KAT cells that have been transduced with a retrovirus ex-
pressing human PIM1-specific siRNA, leading to significant 
down-regulation of PIM1 protein expression (Fig. S8 A). 
Figure 6. Functional inhibition of PIM1 impairs surface expression or reexpression of CXCR4. (A) Delayed ligand-induced surface expression or 
reexpression of CXCR4 in the presence of PIM1 inhibitor shown by flow cytometric evaluation in JURKAT cells. 0.5-h treatment with 10 nM CXCL12 before 
wash allows induction of recycling of CXCR4 on the cell surface evaluated 1, 2, and 3 h after wash compared with nonwashed cells. Recycling is delayed 
when cells are pretreated for 1 h with 10 µM of the PIM inhibitor (K00486). Data represent the mean of three independent experiments. (B) Confocal  
immunofluorescence analysis of distribution of CXCR4 in JURKAT cells after 3.5 h of treatment as mentioned in A. The left column shows CXCR4 distribution 
without PIM inhibitor, the right column shows CXCR4 distribution with treatment of 10 µM of the PIM inhibitor (K00486). The figure illustrates one out of 
three independent experiments. Bar, 10 µm. (C) JURKAT E cells were transduced with pLMP hPIM1-siRNA or control vector. After 1 h of treatment with 
CXCL12, the cells were washed. Surface expression of CXCR4 was analyzed before and after CXCL12 stimulation and 1, 2, and 3 h after wash. Data repre-
sent the mean ± SD of two independent experiments performed in duplicates.
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in vitro with purified PIM1 protein. A single PIM1-dependent 
phosphorylation was detected by a shift of +80 Da in the in-
tact protein mass as determined by electrospray ionization liquid 
chromatography/mass spectrometry, whereas no phosphory-
lation was detected on GST alone. To further define the 
phosphorylation site, a series of C-terminal deletion constructs 
(Busillo and Benovic, 2007). We identified three putative PIM1 
consensus sites in this region (S325, S330, and S339) contain-
ing either the preferred -5 or -3 arginine (position relative to 
the target serine; Fig. 7 A). To assess their potential as a PIM1 
phosphorylation site, the C-terminal 46 residues of CXCR4 
were expressed as a GST fusion protein (GST-C46) and treated 
Figure 7. PIM1 phosphorylates the CXCR4 C terminus at serine 339. (A) Deletion series defining the CXCR4 C-terminal region phosphorylated by 
PIM1. Schematic representation of human CXCR4 showing the C-terminal 46 aa expressed as a GST fusion (CXCR4 region boxed in blue). Three putative 
PIM1 recognition sites are shown in red. A series of C-terminal truncations map PIM1 phosphorylation to a peptide region including S339 (indicated by 
shaded area; ESI-LC/MS spectra, not shown). (B) Identification of Ser339 as a PIM1 phosphorylation site. MALDI TOF spectra of an 11-mer CXCR4 peptide 
(shaded sequence from A) show PIM1 phosphorylation of the WT sequence but not of a mutant S339A peptide. Inset box shows detail of the WT phos-
phorylation with or without PIM1 treatment. Spectra of the phosphorylated peptide are offset for clarity. The figure represents one out of two indepen-
dent analyses. (C) In vitro kinase assay performed with different CXCR4 C-terminal mutants confirms that CXCR4 is phosphorylated by PIM1 at serine 
339. Protein is detected by anti-PIM1 or anti–phospho-CXCR4 (Ser339) antibody. The blot represents one out of three independent experiments.  
(D, top) Determination of the CXCR4-Ser339 phosphorylation state in JURKAT cells incubated for 0.5 h with 10 nM CXCL12 or 40 nM PMA with or without 
a 1-h pretreatment with 10 µM of PIM inhibitor (K00486) before a 2-h wash. CXCR4-Ser339 phosphorylation is inhibited in the presence of PIM inhibitor. 
Values are the mean of two independent experiments. (D, bottom) Determination of CXCR4-Ser339 phosphorylation state in JURKAT E cells, transduced 
with pLMP hPIM1-siRNA or control vector and incubated for 0.5 h with 10 nM CXCL12, followed by a 2-h wash. The blot represents one out of two inde-
pendent experiments. (E) In vitro kinase assay performed with CXCR4 C-terminal mutant C46 shows that CXCR4 is phosphorylated by PIM1 at serine 339 
but not by PIM2. BAD phosphorylation was used as positive control to confirm enzyme activity of PIM1 and PIM2. The blot represents one out of two 
independent experiments.
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as well as in PIM knockout mice, suggesting that the loss of 
one PIM can be compensated for by deregulation of the others 
(Mikkers et al., 2004). However, there are studies suggesting 
that in some situations, the loss of a particular PIM kinase may 
not be compensated for by the presence of other PIMs. For 
example, the growth of bone marrow–derived mast cells from 
PIM1 knockout animals is significantly reduced despite induc-
tion of PIM2 by IL-3 (Domen et al., 1993). Our present work 
clearly demonstrates that in primary mouse bone marrow cells 
expressing FLT3-ITD, the lack of PIM1 cannot be compen-
sated for by the presence of PIM2. Using bone marrow recon-
stitution assays, we show that FLT3-ITD induces a lethal 
myelo- and lymphoproliferative disorder in vivo in the absence 
of PIM2. Interestingly, PIM1/ cells expressing an empty 
retrovirus (MigRI) or FLT3-ITD transplanted in a sublethally 
irradiated host were detectable but gradually declined over 
several weeks after transplant (unpublished data). Transplanta-
tion of an identical number of PIM1/ cells into lethally irra-
diated hosts resulted in early death (2–4 wk) of all recipients, 
suggesting that cells lacking PIM1 have an inherent homing 
defect, which was further confirmed in a series of experiments 
measuring homing to the bone marrow and the spleen 4 and 
20 h after transplant (Fig. 2). However, expression of FLT3-ITD 
in bone marrow cells from PIM1/ mice resulted in gen-
erally impaired growth in vitro (Fig. 1 and Fig. S1), indicating 
that these cells do not only display a homing defect but also 
have a growth disadvantage compared with WT or PIM2/ 
bone marrow cells.
Homing of HSCs to the bone marrow niche is a complex 
and still poorly understood process involving several signaling 
pathways. There is strong evidence that interaction of the 
chemokine CXCL12, which is expressed on stroma cells, 
with its receptor CXCR4, which is expressed on HSCs, plays 
an essential role in this process (Juarez and Bendall, 2004; 
Lapidot et al., 2005; Burger and Kipps, 2006; Ratajczak et al., 
2006). Proper functioning of the CXCL12–CXCR4 axis 
seems to be crucial for directing homing/engraftment of nor-
mal, as well as leukemic, HSCs into bone marrow after trans-
plantation (Peled et al., 1999; Tavor et al., 2004). Our results 
provide strong evidence that PIM1 can functionally regu-
late CXCR4. Absence of PIM1 is associated with impaired 
CXCL12-induced Ca2+ flux and activation of downstream 
effectors (Fig. 3). In addition, functional down-regulation by 
siRNAs, expression of a dominant-negative–acting kinase-dead 
mutant, or treatment with a small molecule PIM kinase in-
hibitor leads to down-regulation of CXCR4 expression at 
the surface of hematopoietic cells (Figs. 4 and 5). In addition, 
colocalization studies, as assessed by immunofluorescence, and 
in vitro kinase assays suggest that PIM1 may directly modify 
the intracellular C-terminal domain of CXCR4 (Fig. 7 and 
Fig. S8 B). However, we cannot rule out that kinase-active 
PIM1 indirectly regulates the phosphorylation of CXCR4 
through another yet unidentified kinase.
Our results show that PIM1 regulates surface expression 
of CXCR4. PIM1/ hematopoietic cells have a subtle but 
measurable defect in cytokine-mediated proliferation (Domen 
were prepared, treated with PIM1, and analyzed by mass 
spectrometry. Phosphorylation was observed for short dele-
tions, including the construct GST-C4613, but was lost 
upon further truncation, locating the likely substrate site to 
the C-terminal residue S339 (Fig. 7 A). To confirm this result, 
the phosphorylation reaction was repeated with an 11-mer 
peptide derived from this site and a similar peptide containing 
the mutation S339A (Fig. 7 B). Importantly, MALDI TOF 
experiments revealed PIM1-dependent phosphorylation of 
the WT peptide but not the S339A mutant peptide. This data 
suggests that PIM1 regulation of CXCR4 results from direct 
phosphorylation of the C-terminal domain. Generation of a 
phosphospecific antibody has previously allowed the demon-
stration that phosphorylation of CXCR4-S339 occurs upon 
stimulation of brain cancer cells by CXCL12 or by phorbol-
ester or EGFR (Woerner et al., 2005). We used this antibody 
in a series of in vitro kinase assays to show that PIM1-depen-
dent phosphorylation of CXCR4 was lost specifically in the 
S339A mutant but not in the mutants S325A or S330A, which 
correspond to the other putative PIM1 recognition sites (Fig. 
7 C). Treatment of JURKAT cells with the PIM1 inhibitor 
K00486 resulted in reduced CXCL12 and PMA-induced 
phosphorylation of CXCR4-S339 (Fig. 7 D, top). Similarly, 
reduced CXCL12-induced phosphorylation of CXCR4-S339 
was observed upon siRNA-mediated knockdown of PIM1 
(Fig. 7 D, bottom). In vitro kinase assays furthermore demon-
strated that PIM1, but not PIM2, is able to efficiently phos-
phorylate CXCR4-S339, whereas BAD is phosphorylated by 
both kinases to a similar extent (Fig. 7 E). These observations 
suggest that kinase active PIM1, but not PIM2, can regulate 
CXCR4 phosphorylation.
DISCUSSION
Several lines of evidence suggest that the family of PIM ser-
ine/threonine kinases plays an important role in the patho-
genesis of hematological malignancies. PIM kinases have been 
reported as being deregulated by oncogenic PTK fusions, such 
as the FLT3-ITD mutant found in up to a third of human 
AMLs. These studies have produced partly conflicting results 
regarding the role of PIM1 or PIM2 (which are both expressed 
in the hematopoietic system) in the pathogenesis of PTK-
mediated leukemogenesis (Mizuki et al., 2003; Kim et al., 2005; 
Adam et al., 2006; Agrawal et al., 2008). Our study addressed 
the role of PIM kinases in primary cells, and the results showed 
that transformation of hematopoietic cells by FLT3-ITD in 
vitro and in vivo is independent of PIM2 (Fig. 1). This finding 
is unexpected, as previous work demonstrated that targeting 
of PIM2 by siRNA or by expressing dominant-negative 
kinase dead mutants (PIM-KD) significantly impaired growth 
and survival or FLT3-ITD–expressing hematopoietic cells 
(Adam et al., 2006; Agrawal et al., 2008). However, the previ-
ous experiments were performed in immortalized cell lines that 
stably express FLT3-ITD, whereas in the present work primary 
mouse bone marrow cells were used.
The PIM kinases have been identified through serial retro-
viral gene tagging in c-myc–induced lymphomas in WT mice, 
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pression. Elevated PIM1 levels frequently observed in leukemia 
and solid tumors would facilitate CXCL12-mediated signal-
ing by increasing surface reexpression of the receptor. This 
hypothesis is supported by our observation of significantly in-
creased migration toward CXCL12 in cells that overexpress 
PIM1 (Fig. 5 C).
Interaction of CXCL12 with CXCR4 does not only pro-
vide signals for efficient migration and homing, but seems also 
to support survival of hematopoietic progenitor cells (Lataillade 
et al., 2002). There is increasing evidence that CXCR4 is a 
key regulator of homing and retention of leukemic stem cells 
within the marrow niche, allowing these cells to escape spon-
taneous and chemotherapy-induced cell death (Juarez and 
Bendall, 2004; Sipkins et al., 2005; Burger and Kipps, 2006). 
These findings are supported by the negative prognostic im-
pact of high CXCR4 expression levels in patients with AML 
(Rombouts et al., 2004; Spoo et al., 2007). Consequently, 
targeting leukemic stem cells within the bone marrow by 
disruption of the CXCL12–CXCR4 interaction by small 
molecule inhibitors has been recently proposed (Zeng et al., 
2006; Juarez et al., 2007).
The association of elevated PIM1 expression with expres-
sion of high levels of surface CXCR4 in leukemic blasts from 
AML patients (Fig. 5 A) suggests that targeting aberrant PIM 
activity by small molecules would be rather promising by its 
effects on interfering not only with self-renewal but also with 
migration and homing of leukemic cells. Indeed, structural 
analysis of PIM1 has allowed us to identify a group of selec-
tive small molecule inhibitors with potent antileukemic ac-
tivity in vitro (Pogacic et al., 2007). Short-term treatment of 
fresh leukemic blasts from six AML patients with the PIM 
inhibitor (K00486) resulted in a significant decrease of steady-
state surface CXCR4 expression in four samples (Fig. 5 B). 
Ongoing experiments aim to understand why some AML 
blasts are resistant to CXCR4 regulation after treatment with 
the PIM inhibitors.
Collectively, we have dissected the role of PIM serine/
threonine kinases for FLT3-ITD leukemogenesis in vitro and 
in vivo. Our work demonstrated that PIM2 is dispensable for 
transformation by FLT3-ITD and cells lacking PIM1 are im-
paired for growth and survival that cannot be overridden by 
FLT3-ITD. Most importantly, our work demonstrates that 
PIM1 activity directs cellular homing and migration by reg-
ulation of surface CXCR4 expression, suggesting that 
increased PIM1 expression supports CXCL12–CXCR4-medi-
ated homing of leukemic stem cells and could also be impli-
cated in metastasis formation in human cancer.
MATERIALS AND METHODS
DNA constructs and growth factors. The complementary DNA 
(cDNA) of mouse FLT3-ITD was provided by H. Serve (University of 
Frankfurt, Frankfurt, Germany). The retroviral vector was constructed by 
cloning the FLT3-ITD cDNA into the MigRI retroviral vector coexpressing 
the green fluorescent protein (EGFP; Grundler et al., 2005). Mouse PIM1 in 
MigRI has been described previously (Pogacic et al., 2007). Retroviral con-
structs (pLMP) expressing mouse and human PIM-specific siRNAs have 
been obtained through Open Biosystems (mPIM1, VMM_46214; mPIM2, 
et al., 1993; Fig. 1). Therefore, it is very likely that impaired 
in vivo homing of PIM1/ marrow cells might be the result 
of inappropriate function of several PIM targets including 
CXCR4. Interestingly, PIM1/ marrow cells do not com-
pletely lack CXCR4. In fact, they express less surface CXCR4, 
most probably as a consequence of inappropriate reexpres-
sion. As PIM1/ mice are viable and have a normal lifespan, 
a lower amount of surface CXCR4 seems to be sufficient to 
regulate steady-state hematopoiesis.
G protein–coupled receptors like CXCR4 are regulated 
by desensitization, internalization, and degradation (Busillo 
and Benovic, 2007). CXCR4 seems to undergo ligand- 
dependent and -independent internalization and surface re-
exposure in hematopoietic cells. In both internalization and 
reexposure of CXCR4, the serine/threonine-rich intracellu-
lar C terminus seems to play a key role (Orsini et al., 1999; 
Pelchen-Matthews et al., 1999). Natural mutants in patients 
with WHIM syndrome, as well as artificial truncation and ala-
nine scanning mutagenesis, have suggested multiple regions in 
the CXCR4 C-terminal domain as potential phosphoaccep-
tor sites (Hernandez et al., 2003). However, although multiple 
protein kinases have been proposed (PKC, GRK3, and GRK6), 
no specific kinase has yet to be clearly implicated (Busillo and 
Benovic, 2007). In this study, we observed that functional in-
terference of PIM1 leads to a decrease in CXCR4 surface ex-
pression, whereas the total amount of the CXCR4 protein 
remains unchanged (Fig. 3). In addition, our work suggests 
that PIM1 regulates surface reexpression, whereas internaliza-
tion of the receptor seems to be not affected (Fig. 6). A similar 
phenotype has been observed in T cells deficient in SYT3 
(synaptotagmin 3), although the underlying mechanism re-
mained unclear (Masztalerz et al., 2007). Our experiments us-
ing mass spectrometry and in vitro kinase assays show that 
PIM1 is able to directly phosphorylate Ser339 in the CXCR4 
C-terminal domain in vitro (Fig. 7). It is worth noting that 
this site is in a motif that closely resembles the consensus PIM 
recognition motif with 5 arginine and 2 histidine although 
the preferred 3 arginine is absent (Bullock et al., 2005a). 
The CXCR4 Ser339 is known being phosphorylated in brain 
cancer cells upon stimulation with CXCL12, phorbol-ester 
(PMA), or EGF (Woerner et al., 2005). Interestingly, both 
CXCL12–CXCR4 and EGF–EGFR lead to activation of the 
JAK–STAT signaling pathway, which regulates PIM1 expres-
sion (Soriano et al., 2003), whereas PMA treatment is also 
known to produce a rapid induction of PIM1 expression 
(Wingett et al., 1996). As some of the PIM1 target sites, like 
the apoptosis regulator BAD (Ser112) or the cell cycle regula-
tor p21(WAF1) (Thr145/Ser146), are also phosphorylated by 
other protein kinases, such as RAF1, PAK5, RSK2/5 for the 
former and PKC- or AKT for the latter (Aho et al., 2004; Jin 
et al., 2005; Kim et al., 2006, Oh et al., 2006; Zhang et al., 
2007), it is unlikely that PIM1 is the only kinase that phos-
phorylates CXCR4-Ser339. Although the exact mechanisms 
remain to be elucidated, based on our results, PIM1-regulated 
phosphorylation of CXCR4-S339 could provide an interac-
tion platform for proteins that regulate receptor surface reex-
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Phosphorylation of GST-CXCR4. PIM1 was expressed and purified as 
described previously (Bullock et al., 2005b). GST-CXCR4 fusions were ex-
pressed in BL21 (DE3) cells with 0.5 mM IPTG induction for 6 h at 18°C. 
Lysates were purified by glutathione sepharose chromatography. Phosphory-
lation reactions were performed for 90 min at room temperature in 125-µl 
samples containing 1 µM PIM1 and 10 µM GST-CXCR4 buffered in 50 mM 
Hepes, pH 7.5, 100 mM NaCl, 1 mM DTT, 1 mM ATP, 5 mM MgCl2, and 
1 mM MnCl2. Control samples were treated similarly in the absence of 
PIM1. Reactions were stopped by the addition of 0.1% formic acid and pro-
tein masses determined by electrospray ionization liquid chromatography/
mass spectrometry.
In vitro kinase assay. 5 µg of recombinant PIM1 or PIM2 was incubated 
at 30°C for 5 min in kinase buffer (40 mM Tris-HCl, pH 7.4, 20 mM 
MgCl2, and 0.1 mg/ml bovine serum albumin) containing 500 µM ATP 
with or without 2 µM PIM inhibitor (K00486; Pogacic et al., 2007). 8 µg of 
the mentioned GST-CXCR4 construct or BAD-purified protein (Milli-
pore) were then added for a further 10 min. The reactions were terminated 
by the addition of Laemmli sample buffer. Phosphorylation of CXCR4 was 
analyzed by Western blotting with anti–phospho-CXCR4 antibody (pro-
vided by J. Rubin, Washington University School of Medicine, St. Louis, 
MO; Woerner et al., 2005). Phosphorylation of BAD was determined by 
Western blotting with anti–phospho-BAD (Cell Signaling Technology). 
Equal loading of substrate was evaluated by using anti-GST (GE Healthcare) 
and anti-BAD (Cell Signaling Technology).
CXCR4 expression after PIM inhibition in AML patient samples. 
Mononuclear cells from peripheral blood from AML patients with >90% of 
leukemic cells were freshly purified using Ficoll gradient. Cells were washed 
in PBS and seeded in 24-well plates with 106 cells/ml of media containing 
RPMI and 10% FCS. Cells were treated with DMSO and 5 or 10 µM 
K00486. After 30 min of treatment, cells were fixed in 3.75% PFA, and 
CXCR4 surface expression was measured using APC-conjugated anti–
human CD184 (12G5) antibody. The work with clinical samples was approved 
by the ethics board of the Albert-Ludwigs-University Freiburg, Germany 
(Project 163/03).
Regulation of CXCR4 surface expression. JURKAT or JURKAT-E 
(transduced with pLMP of pLMP-hPIM1) cells were plated in RPMI com-
plete at a concentration of 105/ml and pretreated for 1 h with 10 µM K00486 
or DMSO at 37°C, as indicated. After this treatment, cells were incubated for 
30 or 60 min with 10 nM CXCL12 at 37°C. Half of the cells were washed 
three times in PBS to remove CXCL12 and K00486 and resuspended in new 
medium, and the rest were left in the original medium. Samples were col-
lected right after the CXCL12 treatment and 1, 2, and 3 h after washing. Cells 
were fixed in 4% PFA. Surface CXCR4 was analyzed by staining with APC-
conjugated anti–human CD184 (12G5) antibody. Nonspecific binding was 
determined using the APC-conjugated rat IgG2b as isotype control (BD).
Determination of intracellular Ca2+ flux. The increase in the intracellu-
lar calcium concentration ([Ca2+]i) induced by CXCL12 was monitored by 
fluorescence spectrophotometry. Freshly isolated BM cells were loaded with 
1 µM Fura-2-AM (Invitrogen) in calcium buffer (137 mM NaCl, 2.7 mM 
KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5.6 mM glucose, and 0.1% BSA buff-
ered with 20 mM Hepes, pH 7.4). After incubation at 37°C for 30 min, cells 
were washed twice and suspended in calcium buffer to a final concentration 
of 2 × 106 cells/ml. Fura-2 fluorescence was monitored in an LS50B lumi-
nescence spectrophotometer (PerkinElmer). The excitation wavelengths used 
were 340 and 380 nm; emission was measured at 510 nm. [Ca2+]i was calcu-
lated from the Grynkiewicz equation. The Kd used was 224 nM. Rmax was 
obtained after lysis of the cells with 0.1% Triton X-100, and Rmin was deter-
mined by addition of 10 mM EGTA.
Confocal microscopy analysis. JURKAT cells were flattened on a glass 
slide, fixed with acetone for 3 s, and dried overnight. Cells were treated 
VMM_194110; hPIM1, V2HS_170016). A cDNA fragment coding for the 
46 C-terminal CXCR4 residues (pcDNA3-hCXCR4fusin was provided by 
V. Piguet, Geneva University Hospital, Geneva, Switzerland) and various 
deletion and point mutants were generated by PCR and cloned into pGEX-
2T. pcDNA3.1-HA-hCXCR4 was provided by M. Biard-Piechaczyk (Insti-
tut de Biologie, Montpelier, France). Recombinant IL-3, IL-6, and mouse 
stem cell factor were purchased from R&D Systems.
Cell culture, retrovirus preparation, and helper virus assay. Mouse 
Ba/F3 cells were grown in RPMI-1640 containing 1 ng/ml IL-3 and 10% 
FCS. Human JURKAT T cells were obtained through the DSMZ (Braunsch-
weig, Germany) and kept in RPMI-1640 containing 10% FCS. Retrovirus 
preparation was performed as described previously (Grundler et al., 2005).
Transduction and transplantation of mouse bone marrow. Syngenic 
bone marrow transplantations were performed as previously described (Grundler 
et al., 2005). Bone marrow was harvested from FVB/N (WT), FVB/N 
PIM1/, and FVB/N PIM2/ donor mice (provided by A. Berns and M. 
Nawijn, The Netherlands Cancer Institute, Amsterdam, Netherlands) and 
incubated overnight in IMDM/20% FCS supplemented with growth factors 
(10 ng/ml mIL-3, 10 ng/ml mIL-6, and 50 ng/ml mouse stem cell factor). 
Cells were transduced in four rounds of spin infection (1,200 g, 32°C, 90 
min) with 4 µg/ml polybrene (Sigma-Aldrich). Subsequently, cells were re-
suspended in HBSS (Sigma-Aldrich) and injected into the tail vein of suble-
thally (750 rad) or lethally (900 rad) irradiated FVB/N recipient mice. All 
procedures were performed in compliance with the German animal welfare 
law, reviewed by the supervisory animal care committee of the Technical 
University Munich, and approved by the government of Upper Bavaria.
Flow cytometric immunophenotyping (FACS analysis). Single-cell 
suspensions of indicated tissue samples were prepared by passing tissue through 
100-µm nylon mesh strainers (Falcon; BD). Red blood cells of peripheral 
blood were lysed before analysis. Cells were preincubated with Fc block and 
CD45-PECy5 and subsequently stained with PE-conjugated anti-CD11b 
(Mac-1), CD45R/B220, CD90.1 (Thy1.1), CD4, or CD8- antibodies as 
indicated. Dead cells were excluded by propidium iodide (PI) or 7-amino-
actinomycin D (7-AAD) staining as mentioned in the text. Cell surface ex-
pression of CXCR4 was analyzed by staining with PE-conjugated anti–mouse 
CD184 (2B1) or APC-conjugated anti–human CD184 (12G5) antibodies 
(BD). Unspecific binding was assessed by a PE- or APC-conjugated rat IgG2b 
as an isotype control. Fc block and all antibodies were purchased from BD.
Bone marrow cell homing. Female recipient FVB/N mice were lethally 
irradiated (900 rad) 24 h before transplantation. Donor cells of PIM1/ or 
WT FVB/N mice were stained with 1 µM CFSE (Invitrogen) according to 
the manufacturer’s instructions. Comparable staining and viability of labeled 
cells was determined by flow cytometry (FACS). Subsequently, cells were re-
suspended in HBSS and irradiated mice received transplants of 106 CFSE-
stained and viable bone marrow cells via tail vein injection. Mice were killed 
4 or 20 h after transplantation as indicated. Single cell suspensions were incu-
bated with Fc-blocking reagent and subsequently stained with PE-CY5–con-
jugated anti-CD45 antibody. Dead cells were excluded by PI staining. Donor 
cells in bone marrow and spleen were detected by flow cytometry. The 
CFSE-stained cells were concurrently cultured in IMDM/20% FCS supple-
mented with growth factors, and viability was determined by PI staining after 
4 and 20 h to exclude differences in viability during the homing process.
Cellular migration analysis. 5 × 105 bone marrow cells from PIM1/, 
PIM2/, and WT FVB/N mice were allowed to migrate 4 h toward a 
300-ng/ml CXCL12 gradient using 5.0-µm pore size transwell chambers 
(Costar). The migration index was calculated as a percentage of input cells. 
For Ba/F3 and JURKAT cells, migration toward a 10-nM CXCL12 gradi-
ent was allowed for 4 h using transwell chambers, when indicated cells were 
pretreated for 2 h with 10 µM K00486.
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a myeloproliferative disease in mice transplanted with FLT3-ITD express-
ing WT or PIM2/ but not PIM1/ bone marrow. Fig. S3 shows that 
the absence of PIM2 does not affect the FLT3-ITD–induced phenotype 
in vivo and summarizes all transplant experiments. Fig. S4 shows the he-
matopoietic reconstitution of mice transplanted with WT, PIM1/, and 
PIM2/. Fig. S5 shows that PIM1 does not influence integrin-4/5 ex-
pression. Fig. S6 shows ERK phosphorylation in lineage-negative PIM1/ 
cells. Fig. S7 shows that the expression of a dominant-negative PIM1 mutant 
decreases surface CXCR4 expression and that the inhibition of PIM affects 
CXCL12-induced ERK phosphorylation. Fig. S8 shows the knockdown 
efficacy of PIM1 and the immunolocalization of PIM1 and CXCR4 in 
JURKAT cells. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20082074/DC1.
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